Steris extends advisory role for former CFO Michael J. Tokich with reduced salary
Steris plc announced an amendment to its transition agreement with former CFO Michael J. Tokich, extending his role as a senior financial advisor for one year, from April 1, 2026, to March 31, 2027. During this period, his annual base salary will be reduced to $60,000, and he will no longer receive employee benefits, though he remains eligible for a discretionary cash bonus. STERIS recently reported strong fiscal third-quarter 2026 earnings with high-single-digit revenue growth and maintained its quarterly dividend.
Steris extends advisory role for former CFO Michael J. Tokich with reduced salary
Steris plc (NYSE:STE) announced an amendment to its transition agreement with former CFO Michael J. Tokich, extending his role as a senior financial advisor for one year, from April 1, 2026, to March 31, 2027. During this period, his annual base salary will be reduced to $60,000, and he will no longer be eligible for certain employee benefits, although he remains eligible for a discretionary cash bonus. This follows recent positive fiscal Q3 2026 earnings for Steris, with strong revenue growth and a maintained dividend.
STERIS extends Michael J. Tokich as senior financial advisor with reduced pay
STERIS (STE) has extended Michael J. Tokich's post-executive employment as a part-time senior financial advisor until March 31, 2027. His role comes with a reduced annual base salary of $60,000. This change was formalized through an amendment to his Transition Agreement, following his former position as Chief Financial Officer.
Aberdeen Group plc Buys 20,097 Shares of STERIS plc $STE
Aberdeen Group plc increased its stake in STERIS plc by 25.1% in the fourth quarter, purchasing an additional 20,097 shares, bringing its total holdings to 100,088 shares valued at $25.37 million. STERIS, a medical equipment provider, reported Q4 EPS of $2.53, matching estimates, and a 9.2% increase in revenue year-over-year, while also setting an optimistic FY2026 EPS guidance of 10.15–10.30. The company maintains a "Moderate Buy" consensus rating from analysts, with share performance and dividend information also detailed.
Global Clinical Drainage Supplies Market Dominated by North America as Cardinal Health and Medline Expand Products
The global clinical drainage supplies market is transitioning to a critical infrastructure layer in healthcare, valued at USD 4.5 billion in 2026 and projected to reach USD 8.8 billion by 2036 with a CAGR of 6.9%. Growth is driven by standardization, infection control, and the expansion of integrated kits, with North America dominating and India emerging as the fastest-growing market. Key players like Becton, Dickinson and Company, Cardinal Health, Medtronic, Teleflex, and Getinge compete on portfolio coverage and supply continuity.
Global Clinical Drainage Supplies Market Dominated by North America as Cardinal Health and Medline Expand Products
The global clinical drainage supplies market is projected to grow from USD 4.5 billion in 2026 to USD 8.8 billion by 2036, at a CAGR of 6.9%. This growth is driven by the increasing need for protocol standardization and infection control in surgical and post-acute care, with reliability and seal integrity being key factors for procurement. North America, alongside emerging markets like India and Brazil, is a significant driver of this expansion, while key players such as Becton, Dickinson and Company, and Cardinal Health continue to dominate.
Banque Pictet & Cie SA Purchases New Position in STERIS plc $STE
Banque Pictet & Cie SA has acquired a new stake in STERIS plc (NYSE:STE) during the fourth quarter, purchasing 9,782 shares valued at approximately $2.48 million. This move is part of broader institutional interest, with hedge funds and other institutional investors now owning 94.69% of the company's stock. Analysts currently rate STERIS as a "Moderate Buy" with an average target price of $275.20, following a reported EPS of $2.53 for the last quarter and a revenue increase of 9.2% year-over-year.
Tudor Investment Corp ET AL Lowers Holdings in STERIS plc $STE
Tudor Investment Corp ET AL significantly reduced its stake in STERIS plc (NYSE:STE) by 91.2% in the third quarter, leaving it with 1,807 shares valued at approximately $447,000. Despite this reduction, other institutional investors like Vanguard Group Inc. and State Street Corp increased their holdings. STERIS reported strong Q3 results, meeting analyst EPS estimates and showing a 9.2% year-over-year revenue increase, with a consensus "Moderate Buy" rating from analysts.
In-Depth Examination of Segments, Industry Developments, and Key Players in the Foot and Ankle Devices Market
The foot and ankle devices market is projected to reach $10.77 billion by 2030, growing at a CAGR of 10.2%, driven by advancements in orthopedic care and evolving patient needs. Key trends include customized orthopedic implants, advanced bracing, minimally invasive procedures, and diabetic foot care devices. Technological innovations, such as navigation systems for surgical accuracy, are also significantly impacting the market.
Medical Waste Management Market Size Worth USD 12.83 billion, Globally, by 2030 | CAGR of 5.8%
The global Medical Waste Management Market is projected to grow to USD 12.83 billion by 2030, with a CAGR of 5.8% from 2021 to 2030, up from USD 7.22 billion in 2020. This growth is driven by the increasing volume of medical waste, rising chronic disease prevalence, and higher demand for healthcare services. Offsite treatment and non-hazardous waste segments are expected to lead the market, with Asia-Pacific showing the fastest regional growth.
Assenagon Asset Management S.A. Cuts Holdings in STERIS plc $STE
Assenagon Asset Management S.A. significantly reduced its stake in STERIS plc, selling 94.3% of its shares, bringing its total holdings to 18,742 shares valued at $4.75 million. Despite this large sale, institutional ownership of STERIS remains strong at 94.69%. Analysts generally rate STERIS as a "Moderate Buy" with an average price target of $275.20, while the company reported earnings in line with estimates and set optimistic FY2026 guidance.
STERIS plc Stock: Leader in Infection Prevention and Healthcare Solutions for Long-Term Investor Val
STERIS plc is highlighted as a robust investment in the healthcare sector, providing essential sterilization and infection control solutions to North American healthcare and pharmaceutical industries. The article details its resilient business model, strong market position, and growth catalysts such as aging populations and regulatory pressures, making it an attractive option for long-term investors seeking stability with growth potential. It also addresses risks like reimbursement pressures and supply chain dependencies, while outlining key areas for investors to monitor.
STERIS plc Stock: A Defensive Play in Healthcare Sterilization and Infection Prevention for North Am
STERIS plc (NYSE: STE) is highlighted as a global leader in infection prevention and healthcare solutions, providing essential sterilization products for hospitals and pharmaceutical manufacturers. The company's business model relies on recurring revenue from consumables and services, offering stability for North American investors. The analysis covers its market position, growth opportunities driven by rising healthcare needs, solid financial performance, and key risks such as regulatory changes and supply chain disruptions.
STERIS plc (STEN.MX) Stock Price, News, Quote & History
This article provides the stock price, news, quote, and historical data for STERIS plc (STEN.MX) on Yahoo Finance. It shows that STERIS plc's stock closed at 3,824.43 with no change. The page also includes broader market data for Canada, with indices like S&P/TSX, S&P/TSX Capped Financial, and S&P/TSX Capped Energy showing positive movements, alongside other financial data for CAD/USD, Bitcoin, and Crude Oil.
STERIS plc Stock: A Defensive Play in Healthcare Sterilization and Infection Prevention for North Am
STERIS plc (NYSE: STE) is presented as a defensive investment in healthcare, specializing in infection prevention and sterilization products for hospitals and pharmaceutical companies. The article highlights its stable demand, recurring revenue model from consumables and services, and strong market position, especially in North America. It also discusses growth drivers like rising procedure volumes and stringent regulations, along with financial health, investor relevance, and potential risks such as regulatory changes and supply chain disruptions.
Wealth Enhancement Advisory Services LLC Purchases 5,095 Shares of STERIS plc $STE
Wealth Enhancement Advisory Services LLC increased its stake in STERIS plc by 23.5% in the fourth quarter, purchasing an additional 5,095 shares, bringing their total ownership to 26,763 shares valued at approximately $6.97 million. Institutional investors now collectively own about 94.69% of STERIS. The company reported EPS of $2.53, revenue growth of 9.2% year-over-year, and issued FY2026 EPS guidance between $10.150 and $10.300, while maintaining a "Moderate Buy" analyst consensus with a $275.20 target price.
STERIS plc (Ireland) (STE) Stock Forecasts
This article provides an Argus research report on STERIS plc (STE), an Ireland-domiciled medical technology company specializing in sterilization services. Argus is raising its target price for STE to $244.00, with the current price noted as $218.71. The report summary offers a brief overview of Steris's business focus.
DXCM (DexCom) Earnings Power Value (EPV) : $11.42 (As of Dec25)
This article from GuruFocus.com details the Earnings Power Value (EPV) of DexCom (DXCM), finding it to be $11.42 as of December 25th. The analysis labels DXCM as "Significantly Undervalued" with a GF Score of 91/100, despite having 3 warning signs. The article explains the EPV methodology, which values a stock based on current free cash flow rather than speculative future projections.
Vanguard disaggregates holdings; Vanguard (NYSE: STE) reports 0 shares
Vanguard has filed an amended Schedule 13G/A, reporting 0 shares beneficially owned in STERIS PLC (STE) after an internal realignment on January 12, 2026. This change reflects Vanguard's decision that certain subsidiaries will now report their ownership separately, relying on SEC Release No. 34-39538, rather than indicating a sale of shares. The filing states that The Vanguard Group thus no longer has beneficial ownership over securities held by these subsidiaries.
Steris PLC stock outperforms competitors despite losses on the day
On Friday, Steris PLC (STE) shares dropped by 1.80% to $219.40, breaking a six-day winning streak, despite an overall dismal trading session where both the S&P 500 and Dow Jones Industrial Average also fell significantly. The stock's performance still managed to outperform its competitors on the day.
UAE Dental Devices Market Is Going to Boom Rapidly |3M Company,
This press release announces a market research report on the UAE Dental Devices Market, forecasting rapid growth between 2026 and 2033. The report offers detailed insights into market structure, segmentation, key players like 3M Company and Dentsply Sirona, and strategic recommendations for businesses. It covers product types, treatments, and end-user segments, aiming to help stakeholders capitalize on emerging opportunities in the evolving market landscape.
PAR Technology Corporation (NYSE:PAR) Given Consensus Recommendation of "Moderate Buy" by Brokerages
PAR Technology Corporation (NYSE:PAR) has received a consensus "Moderate Buy" rating from seven brokerages, with an average 12-month price target of $34.20, despite some recent target reductions. Insider transactions show major shareholder Voss Capital increasing its stake while CEO Savneet Singh reduced his holding. The company recently exceeded Q4 earnings and revenue expectations but remains unprofitable, with its stock trading significantly below analyst targets and its 52-week high.
STERIS Plc Forms Death Cross, Signaling Potential Bearish Trend Ahead
STERIS Plc has experienced a "Death Cross" technical event, where its short-term moving average fell below its long-term moving average, suggesting a bearish market trend. While the stock saw a 1.08% gain today, its one-year performance of 0.17% significantly trails the S&P 500, and it has declined 11.89% year-to-date. Technical indicators show mixed signals, with bearish trends in MACD and Bollinger Bands, indicating potential downward pressure and increased volatility for the company.
SG Americas Securities LLC Has $39.84 Million Stock Position in STERIS plc $STE
SG Americas Securities LLC significantly increased its stake in STERIS plc by 10,510.1% during Q4, now holding 157,135 shares valued at approximately $39.84 million. This move makes the firm own 0.16% of STERIS. Concurrently, a director, Cynthia L. Feldmann, reduced her position by selling 3,098 shares, now owning 1.07% of the company as insiders. STERIS plc currently holds a "Moderate Buy" rating from analysts with an average target price of $275.20, and the company recently reported quarterly earnings in line with estimates and provided optimistic FY26 guidance.
Steris plc stock faces scrutiny amid healthcare sector pressures and proxy season buildup
Steris plc (ISIN: IE00BFY8C754), a leader in infection prevention, is navigating a challenging healthcare environment as proxy season approaches. The company's stock has remained steady due to its strong position in essential healthcare services, particularly benefiting from its critical role in sterilization and endoscopy solutions. US investors are interested in Steris's resilient margins, market dominance, and consistent performance across its Healthcare, Applied Sterilization Technologies, and Life Sciences segments, despite broader sector headwinds and potential regulatory and competitive challenges.
Steris plc stock faces scrutiny amid healthcare sector pressures and proxy season buildup
Steris plc, a leader in infection prevention and sterilization, is facing scrutiny as proxy season approaches, navigating a challenging healthcare environment. US investors are closely watching the company's resilient margins and US market dominance, despite macroeconomic uncertainties. The company's diversified business model, including healthcare, applied sterilization technologies, and life sciences, positions it for long-term resilience and steady top-line expansion.
Steris plc stock faces scrutiny amid healthcare sector pressures and infection prevention demand shi
Steris plc, a global leader in infection prevention and healthcare sterilization, is under investor scrutiny due to rising operational costs and evolving hospital budgets. Despite challenges, the company demonstrates resilience with over 70% of its revenue coming from recurring consumables and services. Steris benefits from its essential role in hospital workflows, particularly with increasing regulatory focus on sterility, and maintains strong financial health.
Haemonetics Corp stock faces uncertainty amid lack of fresh catalysts in blood management sector
Haemonetics Corp stock is currently in a holding pattern due to a lack of fresh catalysts in the blood management sector, despite steady demand for its plasma collection and transfusion technologies. The company, a leader in automated blood processing, benefits from recurring disposable sales in its Plasma and Blood Center segments. Investors should consider the company's solid financial health and
Park Avenue Securities LLC Purchases 5,165 Shares of STERIS plc $STE
Park Avenue Securities LLC significantly increased its stake in STERIS plc by 279%, acquiring an additional 5,165 shares to own a total of 7,016 shares, valued at approximately $1.78 million. This move comes as STERIS reported strong Q4 results, with EPS meeting estimates and revenue up 9.2% year-over-year, alongside a healthy market cap and a consensus price target of $275.20. Despite a director's recent sale of 3,098 shares, institutional investors collectively own a substantial 94.69% of the medical equipment provider's stock.
Nordea Investment Management AB Has $13.17 Million Stock Holdings in STERIS plc $STE
Nordea Investment Management AB significantly increased its stake in STERIS plc, boosting its holdings by 259.0% to 51,602 shares, now valued at approximately $13.17 million. This move coincides with STERIS reporting strong quarterly earnings of $2.53 EPS, a 9.2% increase in revenue year-over-year, and providing an optimistic FY 2026 EPS guidance of $10.15–$10.30. Analysts currently hold a "Moderate Buy" consensus rating for the company with a target price of $275.20.
Philips debuts coronary platform aimed at saving up to 47% of system time
Philips has launched IntraSight Plus, an interventional cardiology platform cleared by the FDA and CE Mark, designed to simplify coronary interventions and enhance precision care. This system integrates various diagnostic and treatment planning tools onto a single screen, claiming to save up to 47% of system operation time. The first patient case using IntraSight Plus was successfully performed on March 19, 2026, enabling complete revascularization through integrated tri-registered imaging and physiology.
STERIS plc $STE Shares Bought by Congress Asset Management Co.
Congress Asset Management Co. increased its holdings in STERIS plc (NYSE:STE) by 6.4% in the fourth quarter, bringing its total to 141,722 shares valued at approximately $35.93 million. This comes as institutional ownership in STERIS is notably high at 94.69%, with several major investment firms holding multi-million share positions. STERIS recently met analyst expectations with Q4 EPS of $2.53, reported a 9.2% year-over-year revenue increase, and issued positive FY2026 EPS guidance, reinforcing its "Moderate Buy" analyst consensus.
Is There Now An Opportunity In STERIS plc (NYSE:STE)?
STERIS plc (NYSE:STE) has seen significant price movements recently and is currently trading at US$221. According to Simply Wall St's valuation model, the stock is fairly priced, approximately 6.4% below its intrinsic value of $236.20. With an optimistic future outlook projecting 43% profit growth, investors are encouraged to consider the company's balance sheet and analyst forecasts before making investment decisions due to its current fair valuation.
Carderock Capital Management Inc. Buys 7,344 Shares of STERIS plc $STE
Carderock Capital Management Inc. significantly increased its stake in STERIS plc (NYSE:STE) by 24.7% in Q4, acquiring an additional 7,344 shares, bringing its total holdings to 37,085 shares valued at $9.402 million. This move positions STERIS as Carderock Capital's 16th largest holding, representing 2.3% of its portfolio. The article also highlights strong institutional interest in STERIS, with Norges Bank initiating a large stake and AQR Capital Management boosting its position, contributing to a high institutional ownership of 94.69%.
Mettler-Toledo Posts Q4 Beat and $900 Million FCF Guide: Breaking Down the $1,754 Target
Mettler-Toledo (MTD) beat Q4 sales and raised 2026 EPS guidance, demonstrating resilience against tariff headwinds and benefiting from a new Switzerland trade deal. The company is poised for growth with an expanding product inspection segment, significant R&D investment, and a strong free cash flow target of $900 million in 2026, alongside substantial share repurchases. A TIKR valuation model supports a $1,754.20 target due to accelerating share capture and sustained margin despite industry pressures.
Swiss Life Asset Management Ltd Has $6.11 Million Position in STERIS plc $STE
Swiss Life Asset Management Ltd increased its stake in STERIS plc by 35.2% to 24,697 shares, now valued at $6.11 million. Institutional investors collectively own 94.69% of the company, which has a "Moderate Buy" consensus rating from analysts with an average target price of $275.20. STERIS recently reported quarterly EPS of $2.53, revenue up 9.2% year-over-year, and declared a quarterly dividend of $0.63.
Analysts Offer Insights on Industrial Goods Companies: FedEx (FDX) and Innovative Solutions And Support (ISSC)
Two analysts have issued bullish sentiments for companies in the Industrial Goods sector. Stephens analyst Reed Seay maintained a Buy rating on FedEx (FDX) with a target of $435.00, while Northland Securities analyst Bobby Brooks assigned a Buy rating to Innovative Solutions And Support (ISSC) with a price target of $34.00. Both companies show moderate buy consensus among analysts with potential upside from current levels.
Groupama Asset Managment Invests $1.16 Million in STERIS plc $STE
Groupama Asset Management has invested $1.16 million in STERIS plc (NYSE:STE) by acquiring 4,701 shares during the third quarter. This move is part of broader institutional interest, with hedge funds and other investors owning 94.69% of the company's stock. STERIS has also received positive analyst ratings, including "Moderate Buy" consensus and an average target price of $275.20, following strong earnings and dividend announcements.
Steris plc Aktie: Healthcare Infection Prevention Leader Trades Below Fair Value Amid Analyst Confidence
Steris plc (ISIN: IE00BFY8C754), a Dublin-based infection prevention specialist, is trading 8.6% below fair-value estimates on the NYSE, attracting significant institutional investment and analyst upgrades. Despite market headwinds, the company shows strong earnings momentum, margin recovery in its Healthcare segment, and a stable financial position. This valuation discount and growth potential present an attractive opportunity for investors, particularly those in German-speaking regions.
Mirabella Financial Services LLP Invests $2.45 Million in STERIS plc $STE
Mirabella Financial Services LLP has purchased a new position of 9,907 shares, valued at approximately $2.45 million, in STERIS plc (NYSE:STE) during the third quarter. Other institutional investors have also adjusted their holdings in STERIS, which currently has a consensus rating of "Moderate Buy" from analysts with an average price target of $275.20. The article also notes recent insider selling by Director Cynthia L. Feldmann and details STERIS's stock performance, dividend announcement, and company profile.
STERIS plc (NYSE:STE) Receives Average Rating of "Moderate Buy" from Analysts
STERIS plc (NYSE:STE) has received a "Moderate Buy" rating from analysts, with an average 12-month price target of $275.20. The company recently reported quarterly earnings that met consensus estimates and announced a quarterly dividend of $0.63 per share. Institutional investors have been increasing their stakes in STERIS, while a director recently sold shares.
Steris (STE) down 2.2% since last earnings report: Can it rebound?
This article discusses the performance of Steris (STE) stock, which has dropped 2.2% since its last earnings report. It asks whether the company can rebound from this recent dip.
Steris (STE) down 2.2% since last earnings report: Can it rebound?
This article discusses the performance of Steris (STE) stock since its last earnings report, noting a 2.2% decline. It poses the question of whether the stock can rebound, implying an analysis of its future prospects is needed.
Will Healthcare Growth Help STE Beat on Q1 Earnings?
This article analyzes whether healthcare growth will enable STE to surpass its Q1 earnings expectations. It likely delves into market trends within the healthcare sector and STE's specific positioning to assess the potential for a positive financial outcome.
Steris PLC stock underperforms Wednesday when compared to competitors
Steris PLC (STE) stock declined by 1.78% on Wednesday, closing at $216.22, despite the S&P 500 Index and Dow Jones Industrial Average also experiencing losses. This decrease ended a three-day winning streak for the company, reflecting a generally poor trading session across the market. The article was generated by MarketWatch Automation, supported by Dow Jones and FactSet data.
Piper Sandler Maintains Steris PLC(STE.US) With Buy Rating, Maintains Target Price $300
Piper Sandler has reiterated its Buy rating for Steris PLC (STE.US) and maintained its target price at $300. This continued positive outlook suggests the firm's confidence in the company's future performance.
Piper Sandler Maintains Steris PLC(STE.US) With Buy Rating, Maintains Target Price $300
Piper Sandler analyst Jason Bednar has reiterated a Buy rating for Steris PLC (STE.US), maintaining a target price of $300. This recommendation is based on the analyst's historical performance, which shows a 35.6% success rate and an average return of -6.0% over the past year according to TipRanks data. The article emphasizes that this information is for informational purposes only and does not constitute investment advice.
STERIS plc $STE Shares Sold by London Co. of Virginia
London Co. of Virginia reduced its stake in STERIS plc by 4.7% in Q3, selling 38,615 shares, while Director Cynthia L. Feldmann significantly decreased her ownership by selling 3,098 shares. STERIS reported Q3 EPS of $2.53 (in line) and 9.2% year-over-year revenue growth, providing positive FY2026 guidance and announcing a $0.63 quarterly dividend. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $275.20.
Holocene Advisors LP Has $49.50 Million Stock Holdings in STERIS plc $STE
Holocene Advisors LP significantly increased its stake in STERIS plc (NYSE:STE) by 977.7% in the third quarter, now owning 200,045 shares valued at $49.50 million. Other hedge funds also adjusted their positions, and 94.69% of STERIS stock is owned by institutional investors. STERIS recently announced a quarterly dividend of $0.63 per share and generally holds a "Moderate Buy" rating from analysts.
Waste Management grants ex-CFO $1M cash bonus
Waste Management awarded its former finance chief, Devina Rankin, a $1 million cash bonus tied to her retirement and the successful transition of the CFO role to David Reed. Rankin, who served for eight years as CFO and over two decades with the company, acted as an executive advisor after stepping down on November 1 to ensure a smooth handover. The bonus also recognized her significant contributions to integrating the Healthcare Solutions business, which resulted from the acquisition of Stericycle.
